{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-21-000097","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2021-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:16.149138+00:00","generated_at":"2026-06-28T01:29:46.375933+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Myriad Genetics promotes Nicole Lambert to COO effective Jan 1, 2022","bullets":["Appointed COO effective Jan 1, 2022; previously Group President over Oncology, Women's Health, International.","Received one-time award of 10,000 time-based RSUs vesting over 4 years; base salary increased to $499,963.","Lambert has 20-year tenure at Myriad; also serves on board of Arcus Biosciences (NYSE: RCUS)."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-21-000097","json":"https://secwatch.observer/filing/0000899923-21-000097.json","markdown":"https://secwatch.observer/filing/0000899923-21-000097.md","text":"https://secwatch.observer/filing/0000899923-21-000097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992321000097/0000899923-21-000097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992321000097/mygn-20211214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T01:29:46.375933+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6d0c4568db","claim":"Nicole Lambert was appointed as Chief Operating Officer at MYRIAD GENETICS INC.","evidence_excerpt":"On December 14, 2021, Myriad Genetics, Inc. (the “Company”) announced that Nicole Lambert, currently serving as its Group President, Myriad Women's Health, Oncology and International, has been appointed Chief Operating Officer of the Company, effective January 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/899923/000089992321000097/0000899923-21-000097-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}